A Registry Study on HIV-related Lymphoma

NCT ID: NCT05231135

Last Updated: 2023-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-25

Study Completion Date

2029-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AIDS Related Lymphoma HIV Related Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
* HIV-infection at time of lymphoma diagnosis
* Lymphoma diagnosis since 01.01.2010
* Adult patients ≥ 18 years
* Written informed consent

Exclusion Criteria

* HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma
* Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rotkreuzklinikum München gGmbH

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Marcus Hentrich

Head of the Department of Hematology and Oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marcus Hentrich, MD

Role: STUDY_CHAIR

Rotkreuzklinikum München

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Red Cross Hospital Munich

Munich, Select One Option, Germany

Site Status RECRUITING

University Hospital Cologne

Cologne, , Germany

Site Status RECRUITING

Amsterdam University Medical Centers

Amsterdam, , Netherlands

Site Status NOT_YET_RECRUITING

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario de Salamanca

Salamanca, , Spain

Site Status RECRUITING

University Hospital of Wales

Cardiff, , United Kingdom

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany Netherlands Spain United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marcus Hentrich, MD

Role: CONTACT

+49 89 1303 4372

Kai Hübel, MD

Role: CONTACT

+49 221 478 86177

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marcus Hentrich, MD

Role: primary

+49 89 1303 4372

Kai Hübel

Role: primary

+492214786177

Sanne Tonino, MD, PhD

Role: primary

Role: backup

Isabel Regalado Artamendi

Role: primary

Role: backup

Miguel Alcoceba

Role: primary

0034 923 29 11 00 ext. 56610

Emily Hopkins, MD

Role: primary

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IN03/0121

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Managerial Database II
NCT01322217 COMPLETED